Daiichi Sankyo's ADC drug R-DXd has been granted breakthrough therapy designation by the National Medical Products Administration.

On January 22nd, Raludotatug Deruxtecan was granted breakthrough therapy designation by the China National Medical Products Administration Drug Evaluation Center for the treatment of platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer in adult patients who have previously been treated with bevacizumab and have CDH6 expression. Raludotatug Deruxtecan is a CDH6-targeted antibody-drug conjugate developed by Daiichi Sankyo and co-developed with Daiichi Sankyo and Merck.